_MEMBER_AD_imp_1 - 94.0-96.0,_MEMBER_AD_imp_1 - 96.0-98.0,_MEMBER_AD_imp_1 - 98.0-100.0,_LogP_AD_imp_1 - 94.0-96.0,_LogP_AD_imp_1 - 96.0-98.0,_LogP_AD_imp_1 - 98.0-100.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-3.1,-3.4,-5.4,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-3.1,-2,-6.6,hsa04380,Osteoclast differentiation,M111,3,0
1,1,1,-4.4,-3.7,-5.3,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-4.3,-4.3,-6.4,GO:0001775,cell activation,M111,3,0
1,1,1,-2.7,-2.1,-3.3,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M111,3,0
1,1,1,-3.3,-2.3,-5,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-2.8,-2.4,-2.1,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M111,3,0
1,1,1,-3.8,-2.6,-3.2,WP2064,Neural crest differentiation,M111,3,0
0,1,1,0,-2.6,-3,GO:0045785,positive regulation of cell adhesion,M011,2,0
1,0,1,-2.2,0,-2.9,M279,PID RB 1PATHWAY,M101,2,0
1,0,1,-3.3,0,-5.1,GO:0021988,olfactory lobe development,M101,2,0
1,1,0,-2.8,-2.3,0,GO:0045927,positive regulation of growth,M110,2,0
1,0,1,-3.4,0,-2.7,hsa05200,Pathways in cancer,M101,2,0
1,0,1,-2.5,0,-2.5,GO:0030217,T cell differentiation,M101,2,0
0,1,1,0,-2.5,-2,GO:0030323,respiratory tube development,M011,2,0
1,0,1,-2.9,0,-2.6,GO:0050767,regulation of neurogenesis,M101,2,0
1,0,1,-2,0,-2.6,WP4540,Hippo signaling regulation pathways,M101,2,0
1,0,1,-2.4,0,-4.6,GO:0045087,innate immune response,M101,2,0
1,0,1,-3,0,-2,GO:0050777,negative regulation of immune response,M101,2,0
1,0,1,-2.9,0,-5.2,GO:0050778,positive regulation of immune response,M101,2,0
1,0,1,-2.1,0,-3.1,GO:0007507,heart development,M101,2,0
1,0,1,-3.1,0,-3.9,GO:0072089,stem cell proliferation,M101,2,0
0,1,1,0,-2.7,-2.7,GO:0050679,positive regulation of epithelial cell proliferation,M011,2,0
1,0,1,-2.2,0,-3.5,GO:0048598,embryonic morphogenesis,M101,2,0
1,0,1,-2.1,0,-2.1,hsa05224,Breast cancer,M101,2,0
1,0,1,-2.4,0,-2.1,GO:0001934,positive regulation of protein phosphorylation,M101,2,0
0,1,1,0,-2.1,-2.6,GO:0022612,gland morphogenesis,M011,2,0
1,0,1,-2.2,0,-2.5,GO:0045937,positive regulation of phosphate metabolic process,M101,2,0
0,1,1,0,-2.1,-2.7,hsa04625,C-type lectin receptor signaling pathway,M011,2,0
1,0,1,-4.6,0,-5.4,GO:0061351,neural precursor cell proliferation,M101,2,0
1,0,1,-2.8,0,-3.2,GO:0048732,gland development,M101,2,0
0,1,1,0,-3.5,-2,GO:0050678,regulation of epithelial cell proliferation,M011,2,0
1,0,1,-5.3,0,-2.6,GO:2000648,positive regulation of stem cell proliferation,M101,2,0
1,0,1,-2.9,0,-2.6,GO:0048729,tissue morphogenesis,M101,2,0
1,0,1,-2.9,0,-3.3,GO:0051960,regulation of nervous system development,M101,2,0
0,1,1,0,-2,-2.9,GO:0060541,respiratory system development,M011,2,0
0,1,1,0,-2.6,-2.9,GO:0071345,cellular response to cytokine stimulus,M011,2,0
1,0,1,-3.4,0,-2.8,GO:0035239,tube morphogenesis,M101,2,0
0,1,1,0,-2.6,-3,GO:0051251,positive regulation of lymphocyte activation,M011,2,0
1,0,1,-2.3,0,-2.9,GO:0002062,chondrocyte differentiation,M101,2,0
1,1,0,-3,-3.7,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M110,2,0
1,0,1,-2.4,0,-3.2,GO:0032102,negative regulation of response to external stimulus,M101,2,0
1,0,1,-3.6,0,-2.5,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M101,2,0
0,1,1,0,-2.1,-2.6,GO:0050673,epithelial cell proliferation,M011,2,0
1,0,1,-2.2,0,-2.9,WP5373,Osteoarthritic chondrocyte hypertrophy,M101,2,0
0,1,1,0,-2,-2,GO:0060379,cardiac muscle cell myoblast differentiation,M011,2,0
1,0,1,-2.2,0,-3.4,GO:0030855,epithelial cell differentiation,M101,2,0
1,0,1,-2.5,0,-2.2,GO:0002757,immune response-activating signaling pathway,M101,2,0
0,1,1,0,-2,-4.2,hsa04650,Natural killer cell mediated cytotoxicity,M011,2,0
1,0,1,-2.1,0,-2.9,GO:0002253,activation of immune response,M101,2,0
0,1,1,0,-2.2,-2.9,WP4149,White fat cell differentiation,M011,2,0
1,0,1,-2.2,0,-2.5,GO:0010562,positive regulation of phosphorus metabolic process,M101,2,0
1,0,1,-4,0,-4.9,GO:0007405,neuroblast proliferation,M101,2,0
1,0,1,-2.8,0,-2.4,GO:0002683,negative regulation of immune system process,M101,2,0
1,0,1,-2.1,0,-4.3,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M101,2,0
0,1,1,0,-2,-2.7,WP4321,Thermogenesis,M011,2,0
0,1,1,0,-2,-3.3,GO:0030099,myeloid cell differentiation,M011,2,0
1,0,1,-5.1,0,-5.1,GO:1903131,mononuclear cell differentiation,M101,2,0
1,1,0,-4.5,-2.7,0,GO:2000628,regulation of miRNA metabolic process,M110,2,0
1,1,0,-2.4,-3.1,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,0,1,-3.4,0,-2.2,GO:0002764,immune response-regulating signaling pathway,M101,2,0
1,1,0,-3.9,-3.2,0,GO:2000630,positive regulation of miRNA metabolic process,M110,2,0
1,1,0,-2.2,-2.2,0,R-HSA-2559583,Cellular Senescence,M110,2,0
0,1,1,0,-2.8,-2.8,GO:1903037,regulation of leukocyte cell-cell adhesion,M011,2,0
1,0,1,-6.3,0,-3.3,GO:0072091,regulation of stem cell proliferation,M101,2,0
1,0,1,-4,0,-4.4,GO:0045165,cell fate commitment,M101,2,0
1,0,1,-2.4,0,-2.4,R-HSA-9006925,Intracellular signaling by second messengers,M101,2,0
1,0,1,-2.6,0,-4.9,GO:0002250,adaptive immune response,M101,2,0
0,1,1,0,-2.1,-2.8,hsa04970,Salivary secretion,M011,2,0
1,1,0,-2.1,-3.3,0,R-HSA-166520,Signaling by NTRKs,M110,2,0
0,1,1,0,-2.4,-2.8,GO:0050863,regulation of T cell activation,M011,2,0
1,0,1,-2.5,0,-3,GO:0031348,negative regulation of defense response,M101,2,0
1,1,0,-2.4,-2.4,0,GO:0048639,positive regulation of developmental growth,M110,2,0
1,0,1,-2.3,0,-2.9,GO:0007423,sensory organ development,M101,2,0
1,0,1,-3.9,0,-4.4,GO:0030098,lymphocyte differentiation,M101,2,0
1,0,1,-3.9,0,-3.4,hsa05166,Human T-cell leukemia virus 1 infection,M101,2,0
1,0,1,-2.1,0,-2.1,GO:0002698,negative regulation of immune effector process,M101,2,0
1,0,1,-3.4,0,-4.3,GO:0021772,olfactory bulb development,M101,2,0
0,1,1,0,-2.6,-3.4,GO:0050867,positive regulation of cell activation,M011,2,0
1,0,1,-2.5,0,-2.5,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M101,2,0
1,0,1,-2.8,0,-4.1,R-HSA-1280215,Cytokine Signaling in Immune system,M101,2,0
1,0,1,-2.6,0,-2.6,hsa05163,Human cytomegalovirus infection,M101,2,0
1,0,1,-2.4,0,-3.8,GO:0055057,neuroblast division,M101,2,0
1,0,1,-2.7,0,-3.1,GO:0051046,regulation of secretion,M101,2,0
0,1,1,0,-3.2,-3.2,GO:0002274,myeloid leukocyte activation,M011,2,0
0,1,1,0,-2.3,-4.4,hsa05169,Epstein-Barr virus infection,M011,2,0
1,0,1,-2,0,-5.9,GO:0001819,positive regulation of cytokine production,M101,2,0
1,0,1,-2.3,0,-7.2,GO:0021537,telencephalon development,M101,2,0
1,0,1,-3,0,-6.2,GO:0030900,forebrain development,M101,2,0
1,0,1,-2.1,0,-2.5,GO:0042060,wound healing,M101,2,0
0,1,1,0,-2.5,-3.8,GO:0002696,positive regulation of leukocyte activation,M011,2,0
1,0,1,-2.1,0,-2.1,WP4262,Breast cancer pathway,M101,2,0
1,0,1,-2.2,0,-2.2,GO:0001763,morphogenesis of a branching structure,M101,2,0
1,0,1,-2.2,0,-2.7,GO:0060759,regulation of response to cytokine stimulus,M101,2,0
1,1,0,-2.7,-2.7,0,GO:0090270,regulation of fibroblast growth factor production,M110,2,0
1,0,1,-2.2,0,-2.2,GO:0008356,asymmetric cell division,M101,2,0
0,1,1,0,-2.9,-3.3,GO:0050870,positive regulation of T cell activation,M011,2,0
1,0,1,-4.8,0,-4.8,GO:0002521,leukocyte differentiation,M101,2,0
1,0,1,-4.3,0,-2.2,GO:0051090,regulation of DNA-binding transcription factor activity,M101,2,0
0,1,1,0,-2.1,-2.1,GO:0030324,lung development,M011,2,0
1,0,1,-3,0,-3,GO:0002704,negative regulation of leukocyte mediated immunity,M101,2,0
0,1,1,0,-3,-3.9,GO:0022409,positive regulation of cell-cell adhesion,M011,2,0
1,0,1,-2.1,0,-2.1,GO:0002065,columnar/cuboidal epithelial cell differentiation,M101,2,0
1,0,1,-2.8,0,-2.8,WP5434,Pathways in cancer,M101,2,0
0,1,1,0,-3.1,-3.9,GO:0022407,regulation of cell-cell adhesion,M011,2,0
1,1,0,-2.9,-3.7,0,R-HSA-9031628,NGF-stimulated transcription,M110,2,0
0,1,1,0,-2.8,-3.7,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M011,2,0
0,0,1,0,0,-2.9,GO:0050954,sensory perception of mechanical stimulus,M001,1,0
0,0,1,0,0,-2,WP399,Wnt signaling pathway and pluripotency,M001,1,0
0,0,1,0,0,-2.4,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M001,1,0
0,0,1,0,0,-2,GO:1900373,positive regulation of purine nucleotide biosynthetic process,M001,1,0
0,0,1,0,0,-2.4,GO:0007498,mesoderm development,M001,1,0
1,0,0,-3.8,0,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M100,1,0
0,1,0,0,-2.2,0,GO:0032026,response to magnesium ion,M010,1,0
0,0,1,0,0,-3.7,GO:0034762,regulation of transmembrane transport,M001,1,0
0,0,1,0,0,-3,GO:0042110,T cell activation,M001,1,0
0,0,1,0,0,-2.9,GO:0042471,ear morphogenesis,M001,1,0
1,0,0,-2.4,0,0,R-HSA-5654688,SHC-mediated cascade:FGFR1,M100,1,0
1,0,0,-2.4,0,0,GO:0032649,regulation of type II interferon production,M100,1,0
0,0,1,0,0,-2.9,GO:0021952,central nervous system projection neuron axonogenesis,M001,1,0
0,0,1,0,0,-3.2,GO:1901019,regulation of calcium ion transmembrane transporter activity,M001,1,0
0,0,1,0,0,-2,GO:0050729,positive regulation of inflammatory response,M001,1,0
1,0,0,-2.2,0,0,R-HSA-5654687,Downstream signaling of activated FGFR1,M100,1,0
1,0,0,-2.2,0,0,GO:0032695,negative regulation of interleukin-12 production,M100,1,0
1,0,0,-3.1,0,0,GO:1903055,positive regulation of extracellular matrix organization,M100,1,0
0,1,0,0,-2.4,0,GO:0030593,neutrophil chemotaxis,M010,1,0
0,0,1,0,0,-3.8,GO:0051279,regulation of release of sequestered calcium ion into cytosol,M001,1,0
0,0,1,0,0,-2.5,GO:0062009,secondary palate development,M001,1,0
1,0,0,-2.9,0,0,GO:0006109,regulation of carbohydrate metabolic process,M100,1,0
0,1,0,0,-2.6,0,WP5072,Modulators of TCR signaling and T cell activation,M010,1,0
1,0,0,-2.9,0,0,GO:0019217,regulation of fatty acid metabolic process,M100,1,0
0,1,0,0,-3.4,0,GO:0032506,cytokinetic process,M010,1,0
1,0,0,-2.5,0,0,GO:0050866,negative regulation of cell activation,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9674555,Signaling by CSF3 (G-CSF),M010,1,0
0,0,1,0,0,-2,R-HSA-2197563,NOTCH2 intracellular domain regulates transcription,M001,1,0
1,0,0,-3.2,0,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M100,1,0
0,1,0,0,-2,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M010,1,0
1,0,0,-2.7,0,0,GO:1901203,positive regulation of extracellular matrix assembly,M100,1,0
0,0,1,0,0,-2.6,WP254,Apoptosis,M001,1,0
0,0,1,0,0,-3.1,GO:0032412,regulation of monoatomic ion transmembrane transporter activity,M001,1,0
0,1,0,0,-3,0,GO:0030595,leukocyte chemotaxis,M010,1,0
0,0,1,0,0,-2,GO:0006351,DNA-templated transcription,M001,1,0
0,0,1,0,0,-2.2,GO:0045588,positive regulation of gamma-delta T cell differentiation,M001,1,0
0,0,1,0,0,-2.9,GO:0030183,B cell differentiation,M001,1,0
0,0,1,0,0,-4.5,GO:0031343,positive regulation of cell killing,M001,1,0
0,0,1,0,0,-3.5,hsa04666,Fc gamma R-mediated phagocytosis,M001,1,0
1,0,0,-2.4,0,0,GO:0010763,positive regulation of fibroblast migration,M100,1,0
0,0,1,0,0,-2.3,GO:0002718,regulation of cytokine production involved in immune response,M001,1,0
0,0,1,0,0,-2.9,GO:0002720,positive regulation of cytokine production involved in immune response,M001,1,0
1,0,0,-2.4,0,0,R-HSA-114452,Activation of BH3-only proteins,M100,1,0
0,1,0,0,-2.4,0,hsa04658,Th1 and Th2 cell differentiation,M010,1,0
0,0,1,0,0,-2.7,GO:0001773,myeloid dendritic cell activation,M001,1,0
0,0,1,0,0,-3.6,GO:0070848,response to growth factor,M001,1,0
1,0,0,-2.1,0,0,GO:0016331,morphogenesis of embryonic epithelium,M100,1,0
0,0,1,0,0,-2.5,hsa05416,Viral myocarditis,M001,1,0
0,0,1,0,0,-2.2,GO:0003208,cardiac ventricle morphogenesis,M001,1,0
0,0,1,0,0,-2.4,GO:0043269,regulation of monoatomic ion transport,M001,1,0
0,1,0,0,-3.6,0,GO:0050900,leukocyte migration,M010,1,0
0,1,0,0,-3.5,0,GO:0098657,import into cell,M010,1,0
0,1,0,0,-2.3,0,GO:0080171,lytic vacuole organization,M010,1,0
0,0,1,0,0,-2.3,GO:0048812,neuron projection morphogenesis,M001,1,0
0,0,1,0,0,-2.2,GO:0090102,cochlea development,M001,1,0
0,0,1,0,0,-2.7,GO:2001257,regulation of cation channel activity,M001,1,0
0,0,1,0,0,-2.4,GO:0048002,antigen processing and presentation of peptide antigen,M001,1,0
0,0,1,0,0,-3.5,GO:1903169,regulation of calcium ion transmembrane transport,M001,1,0
1,0,0,-3.9,0,0,WP3646,Hepatitis C and hepatocellular carcinoma,M100,1,0
0,0,1,0,0,-2.5,GO:0043403,skeletal muscle tissue regeneration,M001,1,0
1,0,0,-2.1,0,0,GO:0070168,negative regulation of biomineral tissue development,M100,1,0
1,0,0,-2.9,0,0,GO:0046320,regulation of fatty acid oxidation,M100,1,0
1,0,0,-2.4,0,0,GO:0045666,positive regulation of neuron differentiation,M100,1,0
0,0,1,0,0,-2.3,GO:0051147,regulation of muscle cell differentiation,M001,1,0
1,0,0,-2.4,0,0,GO:0035329,hippo signaling,M100,1,0
0,1,0,0,-2.1,0,GO:0008217,regulation of blood pressure,M010,1,0
0,0,1,0,0,-2.6,GO:0071230,cellular response to amino acid stimulus,M001,1,0
0,1,0,0,-2.1,0,GO:2001234,negative regulation of apoptotic signaling pathway,M010,1,0
0,0,1,0,0,-2.4,GO:0001654,eye development,M001,1,0
1,0,0,-2.3,0,0,GO:0032729,positive regulation of type II interferon production,M100,1,0
0,0,1,0,0,-3.6,GO:0050727,regulation of inflammatory response,M001,1,0
1,0,0,-2.8,0,0,hsa05161,Hepatitis B,M100,1,0
1,0,0,-2.4,0,0,R-HSA-111458,Formation of apoptosome,M100,1,0
0,1,0,0,-2.4,0,GO:0030011,maintenance of cell polarity,M010,1,0
0,1,0,0,-3.4,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M010,1,0
0,0,1,0,0,-3.3,GO:0002702,positive regulation of production of molecular mediator of immune response,M001,1,0
0,0,1,0,0,-4.3,GO:0045089,positive regulation of innate immune response,M001,1,0
1,0,0,-3.7,0,0,GO:0031342,negative regulation of cell killing,M100,1,0
0,0,1,0,0,-2.1,GO:2000178,negative regulation of neural precursor cell proliferation,M001,1,0
1,0,0,-2.9,0,0,GO:0046620,regulation of organ growth,M100,1,0
0,0,1,0,0,-2.5,GO:0003177,pulmonary valve development,M001,1,0
0,0,1,0,0,-2.3,GO:0032330,regulation of chondrocyte differentiation,M001,1,0
1,0,0,-2.3,0,0,GO:1903556,negative regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
0,0,1,0,0,-4.4,GO:0051282,regulation of sequestering of calcium ion,M001,1,0
0,0,1,0,0,-2.6,GO:0032890,regulation of organic acid transport,M001,1,0
1,0,0,-2.2,0,0,hsa04060,Cytokine-cytokine receptor interaction,M100,1,0
0,0,1,0,0,-3.1,GO:1904861,excitatory synapse assembly,M001,1,0
1,0,0,-2.5,0,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M100,1,0
1,0,0,-3.2,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
1,0,0,-2.9,0,0,GO:0048661,positive regulation of smooth muscle cell proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0019883,antigen processing and presentation of endogenous antigen,M001,1,0
0,0,1,0,0,-2.2,GO:0098883,synapse pruning,M001,1,0
0,1,0,0,-2.4,0,GO:1902236,negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,M010,1,0
1,0,0,-2.7,0,0,GO:0048638,regulation of developmental growth,M100,1,0
0,0,1,0,0,-3.2,GO:0007517,muscle organ development,M001,1,0
1,0,0,-3.7,0,0,GO:0061180,mammary gland epithelium development,M100,1,0
1,0,0,-2.5,0,0,M60,PID NFAT TFPATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0098868,bone growth,M100,1,0
0,0,1,0,0,-2.7,M124,PID CXCR4 PATHWAY,M001,1,0
0,1,0,0,-2.2,0,GO:0050671,positive regulation of lymphocyte proliferation,M010,1,0
0,1,0,0,-2.2,0,GO:0048934,peripheral nervous system neuron differentiation,M010,1,0
0,0,1,0,0,-4.4,hsa05170,Human immunodeficiency virus 1 infection,M001,1,0
0,0,1,0,0,-2.8,GO:0002886,regulation of myeloid leukocyte mediated immunity,M001,1,0
0,0,1,0,0,-2,GO:0001502,cartilage condensation,M001,1,0
0,1,0,0,-2,0,GO:1904893,negative regulation of receptor signaling pathway via STAT,M010,1,0
0,1,0,0,-2.2,0,GO:0035912,dorsal aorta morphogenesis,M010,1,0
0,0,1,0,0,-2,GO:0150146,cell junction disassembly,M001,1,0
0,0,1,0,0,-2.2,GO:0001944,vasculature development,M001,1,0
0,1,0,0,-3.4,0,GO:0030520,intracellular estrogen receptor signaling pathway,M010,1,0
0,0,1,0,0,-2.9,GO:0140888,interferon-mediated signaling pathway,M001,1,0
0,0,1,0,0,-2.7,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M001,1,0
1,0,0,-2.2,0,0,GO:0050852,T cell receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0042327,positive regulation of phosphorylation,M100,1,0
1,0,0,-3.4,0,0,R-HSA-109606,Intrinsic Pathway for Apoptosis,M100,1,0
0,0,1,0,0,-2.7,R-HSA-9664433,Leishmania parasite growth and survival,M001,1,0
0,0,1,0,0,-3.4,GO:0014706,striated muscle tissue development,M001,1,0
0,0,1,0,0,-2.1,R-HSA-9772573,Late SARS-CoV-2 Infection Events,M001,1,0
0,0,1,0,0,-2.9,GO:0003206,cardiac chamber morphogenesis,M001,1,0
0,0,1,0,0,-2,GO:0051100,negative regulation of binding,M001,1,0
0,0,1,0,0,-3,GO:0002252,immune effector process,M001,1,0
0,0,1,0,0,-2.2,GO:0031076,embryonic camera-type eye development,M001,1,0
0,1,0,0,-2.4,0,GO:1905709,negative regulation of membrane permeability,M010,1,0
1,0,0,-3.4,0,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1912422,Pre-NOTCH Expression and Processing,M100,1,0
1,0,0,-2.7,0,0,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M100,1,0
1,0,0,-2.2,0,0,GO:0002715,regulation of natural killer cell mediated immunity,M100,1,0
0,0,1,0,0,-3,GO:0060760,positive regulation of response to cytokine stimulus,M001,1,0
0,0,1,0,0,-2.2,R-HSA-9679191,Potential therapeutics for SARS,M001,1,0
0,0,1,0,0,-2,GO:0043923,positive regulation by host of viral transcription,M001,1,0
0,0,1,0,0,-2.2,GO:0010959,regulation of metal ion transport,M001,1,0
0,0,1,0,0,-2,GO:0060872,semicircular canal development,M001,1,0
1,0,0,-2.7,0,0,GO:0060534,trachea cartilage development,M100,1,0
0,0,1,0,0,-2.1,hsa04664,Fc epsilon RI signaling pathway,M001,1,0
1,0,0,-2.4,0,0,GO:2000668,regulation of dendritic cell apoptotic process,M100,1,0
0,0,1,0,0,-2.4,GO:0048701,embryonic cranial skeleton morphogenesis,M001,1,0
1,0,0,-2.8,0,0,GO:0001764,neuron migration,M100,1,0
0,1,0,0,-2.6,0,GO:0031396,regulation of protein ubiquitination,M010,1,0
0,0,1,0,0,-3.1,R-HSA-421270,Cell-cell junction organization,M001,1,0
1,0,0,-2.7,0,0,GO:2001053,regulation of mesenchymal cell apoptotic process,M100,1,0
1,0,0,-2.9,0,0,GO:0060334,regulation of type II interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.5,0,0,WP4842,Mammalian disorder of sexual development,M100,1,0
1,0,0,-2.4,0,0,R-HSA-525793,Myogenesis,M100,1,0
0,0,1,0,0,-2,GO:0036342,post-anal tail morphogenesis,M001,1,0
0,1,0,0,-2.2,0,GO:0006997,nucleus organization,M010,1,0
1,0,0,-2.7,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9627069,Regulation of the apoptosome activity,M100,1,0
1,0,0,-2.7,0,0,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M100,1,0
0,1,0,0,-2.1,0,GO:0071709,membrane assembly,M010,1,0
0,0,1,0,0,-2.6,R-HSA-9679506,SARS-CoV Infections,M001,1,0
0,1,0,0,-2.3,0,GO:0006909,phagocytosis,M010,1,0
1,0,0,-3.5,0,0,GO:0060562,epithelial tube morphogenesis,M100,1,0
1,0,0,-2.1,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
0,0,1,0,0,-5.9,R-HSA-877300,Interferon gamma signaling,M001,1,0
1,0,0,-2.2,0,0,R-HSA-111461,Cytochrome c-mediated apoptotic response,M100,1,0
1,0,0,-2.7,0,0,GO:0007512,adult heart development,M100,1,0
0,0,1,0,0,-2.5,GO:0003279,cardiac septum development,M001,1,0
1,0,0,-2.5,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
0,0,1,0,0,-2.2,GO:0009615,response to virus,M001,1,0
0,0,1,0,0,-3.8,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M001,1,0
1,0,0,-2.2,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
1,0,0,-2.1,0,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M100,1,0
0,0,1,0,0,-2.3,WP4787,Osteoblast differentiation and related diseases,M001,1,0
0,0,1,0,0,-3.1,GO:0038093,Fc receptor signaling pathway,M001,1,0
1,0,0,-2.3,0,0,GO:0002823,negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
0,0,1,0,0,-3,GO:1904888,cranial skeletal system development,M001,1,0
0,0,1,0,0,-2.5,GO:0045619,regulation of lymphocyte differentiation,M001,1,0
0,1,0,0,-2.3,0,GO:0042306,regulation of protein import into nucleus,M010,1,0
0,0,1,0,0,-3.7,GO:0048738,cardiac muscle tissue development,M001,1,0
0,1,0,0,-2,0,WP4159,GABA receptor signaling,M010,1,0
1,0,0,-3.6,0,0,WP5087,Pleural mesothelioma,M100,1,0
1,0,0,-2.2,0,0,GO:0032689,negative regulation of type II interferon production,M100,1,0
0,0,1,0,0,-2.1,GO:0003143,embryonic heart tube morphogenesis,M001,1,0
0,1,0,0,-3.1,0,GO:0008037,cell recognition,M010,1,0
0,0,1,0,0,-2.2,GO:2000147,positive regulation of cell motility,M001,1,0
0,1,0,0,-2.1,0,GO:0050878,regulation of body fluid levels,M010,1,0
0,0,1,0,0,-4,R-HSA-418990,Adherens junctions interactions,M001,1,0
0,1,0,0,-2.4,0,M7,PID FCER1 PATHWAY,M010,1,0
1,0,0,-3.9,0,0,WP382,MAPK signaling pathway,M100,1,0
0,0,1,0,0,-2.4,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M001,1,0
1,0,0,-2,0,0,GO:0030502,negative regulation of bone mineralization,M100,1,0
1,0,0,-3.8,0,0,R-HSA-139915,Activation of PUMA and translocation to mitochondria,M100,1,0
1,0,0,-2.4,0,0,WP4537,Hippo YAP signaling,M100,1,0
0,0,1,0,0,-2.2,GO:0003012,muscle system process,M001,1,0
0,0,1,0,0,-2.4,GO:0030335,positive regulation of cell migration,M001,1,0
0,1,0,0,-2,0,GO:1903320,regulation of protein modification by small protein conjugation or removal,M010,1,0
0,0,1,0,0,-2.4,GO:0048339,paraxial mesoderm development,M001,1,0
0,0,1,0,0,-3.9,GO:0045088,regulation of innate immune response,M001,1,0
0,0,1,0,0,-2.2,R-HSA-2029485,Role of phospholipids in phagocytosis,M001,1,0
0,1,0,0,-2.9,0,GO:1902235,regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,M010,1,0
0,0,1,0,0,-3.2,GO:0032680,regulation of tumor necrosis factor production,M001,1,0
0,1,0,0,-2.5,0,GO:0002548,monocyte chemotaxis,M010,1,0
0,0,1,0,0,-2,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M001,1,0
0,1,0,0,-2.2,0,GO:0071353,cellular response to interleukin-4,M010,1,0
0,0,1,0,0,-2.6,hsa04210,Apoptosis,M001,1,0
0,1,0,0,-2.7,0,GO:0050680,negative regulation of epithelial cell proliferation,M010,1,0
0,1,0,0,-2.5,0,R-HSA-9682385,FLT3 signaling in disease,M010,1,0
0,0,1,0,0,-2.1,GO:0022030,telencephalon glial cell migration,M001,1,0
0,0,1,0,0,-2.6,GO:0002711,positive regulation of T cell mediated immunity,M001,1,0
0,0,1,0,0,-2.1,GO:0001701,in utero embryonic development,M001,1,0
1,0,0,-2.1,0,0,GO:0002429,immune response-activating cell surface receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0007162,negative regulation of cell adhesion,M100,1,0
1,0,0,-2.2,0,0,hsa01522,Endocrine resistance,M100,1,0
0,0,1,0,0,-2.4,GO:0009611,response to wounding,M001,1,0
0,1,0,0,-2,0,GO:0010594,regulation of endothelial cell migration,M010,1,0
0,0,1,0,0,-2.1,GO:0032332,positive regulation of chondrocyte differentiation,M001,1,0
1,0,0,-2.4,0,0,GO:0010742,macrophage derived foam cell differentiation,M100,1,0
0,0,1,0,0,-3.4,R-HSA-913531,Interferon Signaling,M001,1,0
0,0,1,0,0,-2.7,GO:2000739,regulation of mesenchymal stem cell differentiation,M001,1,0
0,0,1,0,0,-2,GO:0090036,regulation of protein kinase C signaling,M001,1,0
0,0,1,0,0,-4.6,GO:0043087,regulation of GTPase activity,M001,1,0
0,0,1,0,0,-2.2,GO:0030509,BMP signaling pathway,M001,1,0
0,0,1,0,0,-2.5,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M001,1,0
0,1,0,0,-2.1,0,GO:0044091,membrane biogenesis,M010,1,0
0,0,1,0,0,-2.7,GO:0001914,regulation of T cell mediated cytotoxicity,M001,1,0
1,0,0,-2.2,0,0,R-HSA-190242,FGFR1 ligand binding and activation,M100,1,0
0,0,1,0,0,-3.2,GO:0001910,regulation of leukocyte mediated cytotoxicity,M001,1,0
1,0,0,-3.3,0,0,GO:0045599,negative regulation of fat cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0034103,regulation of tissue remodeling,M100,1,0
0,0,1,0,0,-4.9,GO:0060322,head development,M001,1,0
0,0,1,0,0,-2.3,hsa04714,Thermogenesis,M001,1,0
0,0,1,0,0,-2.6,GO:0032675,regulation of interleukin-6 production,M001,1,0
0,1,0,0,-2.4,0,GO:0002438,acute inflammatory response to antigenic stimulus,M010,1,0
0,0,1,0,0,-4.3,GO:0002699,positive regulation of immune effector process,M001,1,0
0,0,1,0,0,-2.4,GO:0002366,leukocyte activation involved in immune response,M001,1,0
1,0,0,-3.3,0,0,GO:0045598,regulation of fat cell differentiation,M100,1,0
0,0,1,0,0,-2.8,GO:0055123,digestive system development,M001,1,0
0,0,1,0,0,-2.4,GO:0043583,ear development,M001,1,0
0,0,1,0,0,-2.4,GO:0032891,negative regulation of organic acid transport,M001,1,0
1,0,0,-2.5,0,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0050920,regulation of chemotaxis,M100,1,0
0,0,1,0,0,-4.6,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M001,1,0
1,0,0,-3.2,0,0,R-HSA-2559580,Oxidative Stress Induced Senescence,M100,1,0
0,0,1,0,0,-3.2,GO:0034765,regulation of monoatomic ion transmembrane transport,M001,1,0
0,0,1,0,0,-4.1,GO:0031341,regulation of cell killing,M001,1,0
1,0,0,-2.5,0,0,R-HSA-2559585,Oncogene Induced Senescence,M100,1,0
1,0,0,-2.4,0,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-2.3,0,0,GO:0043065,positive regulation of apoptotic process,M100,1,0
0,1,0,0,-2.2,0,GO:0009100,glycoprotein metabolic process,M010,1,0
0,0,1,0,0,-2.3,GO:0060412,ventricular septum morphogenesis,M001,1,0
1,0,0,-2,0,0,GO:0046322,negative regulation of fatty acid oxidation,M100,1,0
0,0,1,0,0,-2.1,GO:0040017,positive regulation of locomotion,M001,1,0
1,0,0,-3.3,0,0,GO:0002832,negative regulation of response to biotic stimulus,M100,1,0
0,1,0,0,-2.4,0,GO:0015015,"heparan sulfate proteoglycan biosynthetic process, enzymatic modification",M010,1,0
0,1,0,0,-2.4,0,WP3945,TYROBP causal network in microglia,M010,1,0
0,1,0,0,-3.2,0,GO:0006897,endocytosis,M010,1,0
1,0,0,-3.1,0,0,GO:0030879,mammary gland development,M100,1,0
1,0,0,-2.4,0,0,GO:0032720,negative regulation of tumor necrosis factor production,M100,1,0
1,0,0,-2.3,0,0,GO:0072175,epithelial tube formation,M100,1,0
0,0,1,0,0,-5.7,WP2849,Hematopoietic stem cell differentiation,M001,1,0
0,0,1,0,0,-2.3,GO:1903708,positive regulation of hemopoiesis,M001,1,0
1,0,0,-2.8,0,0,GO:0120163,negative regulation of cold-induced thermogenesis,M100,1,0
0,0,1,0,0,-2.3,hsa05140,Leishmaniasis,M001,1,0
0,0,1,0,0,-3.2,GO:0002694,regulation of leukocyte activation,M001,1,0
1,0,0,-2.3,0,0,M167,PID AP1 PATHWAY,M100,1,0
1,0,0,-2.5,0,0,GO:0051962,positive regulation of nervous system development,M100,1,0
0,0,1,0,0,-2.2,GO:0001890,placenta development,M001,1,0
0,0,1,0,0,-2.9,GO:0022898,regulation of transmembrane transporter activity,M001,1,0
0,1,0,0,-2.8,0,WP2864,Apoptosis related network due to altered Notch3 in ovarian cancer,M010,1,0
0,0,1,0,0,-2.7,GO:0150063,visual system development,M001,1,0
0,0,1,0,0,-2.4,WP2018,RANKL RANK signaling pathway,M001,1,0
0,0,1,0,0,-2.4,GO:0048514,blood vessel morphogenesis,M001,1,0
1,0,0,-2.8,0,0,GO:0031214,biomineral tissue development,M100,1,0
0,0,1,0,0,-2.5,GO:0032733,positive regulation of interleukin-10 production,M001,1,0
1,0,0,-2,0,0,M1529,SA G1 AND S PHASES,M100,1,0
1,0,0,-2.5,0,0,WP53,ID signaling pathway,M100,1,0
0,0,1,0,0,-2.7,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M001,1,0
0,1,0,0,-2.2,0,GO:0048935,peripheral nervous system neuron development,M010,1,0
0,0,1,0,0,-3.7,GO:0002831,regulation of response to biotic stimulus,M001,1,0
0,0,1,0,0,-2.1,M285,PID HNF3A PATHWAY,M001,1,0
0,0,1,0,0,-2.5,WP4844,Influence of laminopathies on Wnt signaling,M001,1,0
0,0,1,0,0,-2.1,GO:1903115,regulation of actin filament-based movement,M001,1,0
1,0,0,-2.5,0,0,GO:0046622,positive regulation of organ growth,M100,1,0
0,0,1,0,0,-3.1,GO:0002573,myeloid leukocyte differentiation,M001,1,0
0,0,1,0,0,-2.2,GO:0019884,antigen processing and presentation of exogenous antigen,M001,1,0
0,0,1,0,0,-5.5,GO:0019722,calcium-mediated signaling,M001,1,0
1,0,0,-2.7,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
1,0,0,-2.5,0,0,hsa04137,Mitophagy - animal,M100,1,0
0,0,1,0,0,-2,GO:0030216,keratinocyte differentiation,M001,1,0
0,0,1,0,0,-2.9,GO:0038095,Fc-epsilon receptor signaling pathway,M001,1,0
0,0,1,0,0,-3.7,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M001,1,0
0,0,1,0,0,-3.2,GO:0048736,appendage development,M001,1,0
0,0,1,0,0,-2.8,WP2328,Allograft rejection,M001,1,0
0,0,1,0,0,-3.7,GO:0010464,regulation of mesenchymal cell proliferation,M001,1,0
1,0,0,-2,0,0,R-HSA-417957,P2Y receptors,M100,1,0
0,0,1,0,0,-2.9,GO:0002026,regulation of the force of heart contraction,M001,1,0
0,1,0,0,-2.7,0,GO:0000910,cytokinesis,M010,1,0
1,0,0,-2.7,0,0,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M100,1,0
1,0,0,-2.9,0,0,GO:1901201,regulation of extracellular matrix assembly,M100,1,0
1,0,0,-3.7,0,0,GO:0048863,stem cell differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,R-HSA-6803204,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,M100,1,0
0,0,1,0,0,-3.1,GO:0060340,positive regulation of type I interferon-mediated signaling pathway,M001,1,0
1,0,0,-2,0,0,WP5130,Th17 cell differentiation pathway,M100,1,0
0,1,0,0,-2,0,hsa05215,Prostate cancer,M010,1,0
0,1,0,0,-2.9,0,GO:0055080,monoatomic cation homeostasis,M010,1,0
0,0,1,0,0,-4.8,GO:0035113,embryonic appendage morphogenesis,M001,1,0
0,0,1,0,0,-2.2,GO:0046635,positive regulation of alpha-beta T cell activation,M001,1,0
0,0,1,0,0,-2,hsa04514,Cell adhesion molecules,M001,1,0
0,1,0,0,-2.1,0,GO:0002437,inflammatory response to antigenic stimulus,M010,1,0
0,0,1,0,0,-2.4,GO:1903522,regulation of blood circulation,M001,1,0
0,0,1,0,0,-2.3,GO:0043299,leukocyte degranulation,M001,1,0
1,0,0,-2.1,0,0,GO:0045922,negative regulation of fatty acid metabolic process,M100,1,0
0,0,1,0,0,-4.1,GO:0098609,cell-cell adhesion,M001,1,0
0,0,1,0,0,-2.7,M175,PID ERBB2 ERBB3 PATHWAY,M001,1,0
0,0,1,0,0,-2,GO:0033598,mammary gland epithelial cell proliferation,M001,1,0
0,1,0,0,-2.4,0,GO:0001771,immunological synapse formation,M010,1,0
0,0,1,0,0,-2.4,GO:1903305,regulation of regulated secretory pathway,M001,1,0
0,0,1,0,0,-2.6,GO:0002700,regulation of production of molecular mediator of immune response,M001,1,0
0,0,1,0,0,-2.3,GO:0071229,cellular response to acid chemical,M001,1,0
0,0,1,0,0,-2.1,GO:0003002,regionalization,M001,1,0
0,0,1,0,0,-2,GO:0019885,antigen processing and presentation of endogenous peptide antigen via MHC class I,M001,1,0
1,0,0,-4.6,0,0,GO:0140747,regulation of ncRNA transcription,M100,1,0
1,0,0,-2.2,0,0,GO:0060485,mesenchyme development,M100,1,0
0,1,0,0,-2.3,0,GO:0007040,lysosome organization,M010,1,0
0,0,1,0,0,-2,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M001,1,0
0,1,0,0,-2.6,0,hsa05130,Pathogenic Escherichia coli infection,M010,1,0
0,0,1,0,0,-2.2,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M001,1,0
1,0,0,-2,0,0,WP4206,Hereditary leiomyomatosis and renal cell carcinoma pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0001960,negative regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0002520,immune system development,M100,1,0
0,0,1,0,0,-2,GO:0097066,response to thyroid hormone,M001,1,0
0,1,0,0,-2,0,GO:0051642,centrosome localization,M010,1,0
0,0,1,0,0,-2.5,GO:0061448,connective tissue development,M001,1,0
1,0,0,-2.4,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M100,1,0
0,1,0,0,-2.5,0,WP5293,Acute myeloid leukemia,M010,1,0
1,0,0,-3.1,0,0,hsa04010,MAPK signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:1904707,positive regulation of vascular associated smooth muscle cell proliferation,M100,1,0
0,0,1,0,0,-3.8,GO:1902105,regulation of leukocyte differentiation,M001,1,0
0,0,1,0,0,-2.1,GO:0042116,macrophage activation,M001,1,0
0,0,1,0,0,-2.2,hsa04670,Leukocyte transendothelial migration,M001,1,0
0,1,0,0,-2.6,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M010,1,0
0,0,1,0,0,-5.2,GO:0007420,brain development,M001,1,0
0,0,1,0,0,-2.6,GO:0048880,sensory system development,M001,1,0
0,0,1,0,0,-2.2,R-HSA-199418,Negative regulation of the PI3K/AKT network,M001,1,0
0,0,1,0,0,-3.2,hsa04750,Inflammatory mediator regulation of TRP channels,M001,1,0
0,0,1,0,0,-2.7,GO:0044057,regulation of system process,M001,1,0
0,1,0,0,-2.1,0,GO:0042102,positive regulation of T cell proliferation,M010,1,0
0,0,1,0,0,-2.6,hsa04360,Axon guidance,M001,1,0
0,0,1,0,0,-3,GO:0000902,cell morphogenesis,M001,1,0
0,0,1,0,0,-2.5,WP2839,Hair follicle development organogenesis part 2 of 3,M001,1,0
0,0,1,0,0,-2.2,GO:0051588,regulation of neurotransmitter transport,M001,1,0
0,1,0,0,-2.4,0,GO:0030003,intracellular monoatomic cation homeostasis,M010,1,0
1,0,0,-2,0,0,GO:0061138,morphogenesis of a branching epithelium,M100,1,0
0,1,0,0,-2.4,0,GO:0046426,negative regulation of receptor signaling pathway via JAK-STAT,M010,1,0
0,1,0,0,-2.1,0,GO:0032946,positive regulation of mononuclear cell proliferation,M010,1,0
0,0,1,0,0,-2.4,GO:0090257,regulation of muscle system process,M001,1,0
0,1,0,0,-2.3,0,hsa04810,Regulation of actin cytoskeleton,M010,1,0
0,0,1,0,0,-4.5,WP3937,Microglia pathogen phagocytosis pathway,M001,1,0
1,0,0,-2.1,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
0,0,1,0,0,-2,GO:0021756,striatum development,M001,1,0
0,0,1,0,0,-2.4,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M001,1,0
0,0,1,0,0,-2,GO:0046645,positive regulation of gamma-delta T cell activation,M001,1,0
0,0,1,0,0,-2.8,GO:2000177,regulation of neural precursor cell proliferation,M001,1,0
1,0,0,-2.2,0,0,GO:0060421,positive regulation of heart growth,M100,1,0
0,1,0,0,-2.7,0,GO:0032006,regulation of TOR signaling,M010,1,0
0,0,1,0,0,-2.4,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M001,1,0
0,0,1,0,0,-2.9,GO:0071773,cellular response to BMP stimulus,M001,1,0
0,1,0,0,-2.1,0,GO:0070670,response to interleukin-4,M010,1,0
0,0,1,0,0,-2.9,GO:0021700,developmental maturation,M001,1,0
1,0,0,-4.2,0,0,GO:1902895,positive regulation of miRNA transcription,M100,1,0
0,0,1,0,0,-2.7,GO:2000977,regulation of forebrain neuron differentiation,M001,1,0
1,0,0,-2.7,0,0,GO:0002009,morphogenesis of an epithelium,M100,1,0
0,0,1,0,0,-3.1,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M001,1,0
0,1,0,0,-2.9,0,GO:0071407,cellular response to organic cyclic compound,M010,1,0
0,0,1,0,0,-3.2,GO:0050808,synapse organization,M001,1,0
0,0,1,0,0,-3.7,GO:0071363,cellular response to growth factor stimulus,M001,1,0
0,0,1,0,0,-2.7,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M001,1,0
0,0,1,0,0,-3.3,R-HSA-1280218,Adaptive Immune System,M001,1,0
1,0,0,-3.4,0,0,WP5074,Kallmann syndrome,M100,1,0
1,0,0,-2,0,0,GO:0019216,regulation of lipid metabolic process,M100,1,0
1,0,0,-4.1,0,0,GO:0060644,mammary gland epithelial cell differentiation,M100,1,0
0,1,0,0,-2.5,0,GO:0031401,positive regulation of protein modification process,M010,1,0
0,0,1,0,0,-3.1,GO:0043011,myeloid dendritic cell differentiation,M001,1,0
0,0,1,0,0,-4.2,GO:0060627,regulation of vesicle-mediated transport,M001,1,0
0,0,1,0,0,-3.1,hsa05142,Chagas disease,M001,1,0
0,0,1,0,0,-2.8,GO:0006366,transcription by RNA polymerase II,M001,1,0
0,0,1,0,0,-2.6,GO:0003013,circulatory system process,M001,1,0
1,0,0,-2.6,0,0,GO:0050769,positive regulation of neurogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M100,1,0
0,0,1,0,0,-2.2,GO:0038094,Fc-gamma receptor signaling pathway,M001,1,0
0,1,0,0,-2.3,0,GO:0031329,regulation of cellular catabolic process,M010,1,0
0,0,1,0,0,-2.7,GO:1902692,regulation of neuroblast proliferation,M001,1,0
1,0,0,-2.4,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M100,1,0
0,1,0,0,-2.5,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M010,1,0
0,1,0,0,-2.5,0,GO:0032008,positive regulation of TOR signaling,M010,1,0
0,0,1,0,0,-2.1,GO:0043010,camera-type eye development,M001,1,0
0,0,1,0,0,-3.7,R-HSA-9664420,Killing mechanisms,M001,1,0
0,0,1,0,0,-4.8,GO:0030326,embryonic limb morphogenesis,M001,1,0
1,0,0,-2.8,0,0,GO:0002695,negative regulation of leukocyte activation,M100,1,0
0,0,1,0,0,-2.5,GO:0051924,regulation of calcium ion transport,M001,1,0
0,0,1,0,0,-2.2,GO:0045580,regulation of T cell differentiation,M001,1,0
0,1,0,0,-2.7,0,GO:0003073,regulation of systemic arterial blood pressure,M010,1,0
0,0,1,0,0,-2.7,GO:0021955,central nervous system neuron axonogenesis,M001,1,0
0,1,0,0,-2.1,0,GO:0009895,negative regulation of catabolic process,M010,1,0
0,0,1,0,0,-2.5,GO:0043392,negative regulation of DNA binding,M001,1,0
0,1,0,0,-3.3,0,GO:0097529,myeloid leukocyte migration,M010,1,0
1,0,0,-2.5,0,0,GO:1903530,regulation of secretion by cell,M100,1,0
1,0,0,-2.4,0,0,WP4754,IL 18 signaling pathway,M100,1,0
0,0,1,0,0,-2.4,GO:1905809,negative regulation of synapse organization,M001,1,0
0,0,1,0,0,-2.9,GO:0048839,inner ear development,M001,1,0
0,1,0,0,-2.5,0,GO:0001936,regulation of endothelial cell proliferation,M010,1,0
1,0,0,-2,0,0,GO:0048512,circadian behavior,M100,1,0
1,0,0,-2.7,0,0,GO:2001188,regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,M100,1,0
0,0,1,0,0,-2.5,GO:0002218,activation of innate immune response,M001,1,0
0,0,1,0,0,-3.4,GO:0048705,skeletal system morphogenesis,M001,1,0
0,1,0,0,-2.5,0,GO:0030641,regulation of cellular pH,M010,1,0
1,0,0,-2,0,0,GO:0060761,negative regulation of response to cytokine stimulus,M100,1,0
0,1,0,0,-2.3,0,GO:0010256,endomembrane system organization,M010,1,0
0,0,1,0,0,-3.2,GO:0060173,limb development,M001,1,0
1,0,0,-2.4,0,0,M190,PID TCR JNK PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0010640,regulation of platelet-derived growth factor receptor signaling pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0051091,positive regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.7,0,0,GO:0001915,negative regulation of T cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-2.6,GO:0007156,homophilic cell adhesion via plasma membrane adhesion molecules,M001,1,0
0,0,1,0,0,-2.5,GO:0002705,positive regulation of leukocyte mediated immunity,M001,1,0
0,0,1,0,0,-2.3,GO:1902107,positive regulation of leukocyte differentiation,M001,1,0
1,0,0,-4.8,0,0,GO:1902893,regulation of miRNA transcription,M100,1,0
0,1,0,0,-2,0,GO:0007623,circadian rhythm,M010,1,0
1,0,0,-2.4,0,0,hsa05205,Proteoglycans in cancer,M100,1,0
0,0,1,0,0,-3.5,R-HSA-9758941,Gastrulation,M001,1,0
0,0,1,0,0,-2.4,R-HSA-912631,Regulation of signaling by CBL,M001,1,0
0,0,1,0,0,-2.4,GO:0072575,epithelial cell proliferation involved in liver morphogenesis,M001,1,0
0,0,1,0,0,-2.4,GO:0048546,digestive tract morphogenesis,M001,1,0
0,0,1,0,0,-2,WP75,Toll like receptor signaling pathway,M001,1,0
1,0,0,-2.4,0,0,R-HSA-5654693,FRS-mediated FGFR1 signaling,M100,1,0
1,0,0,-4.6,0,0,R-HSA-449147,Signaling by Interleukins,M100,1,0
0,0,1,0,0,-2.2,GO:0019882,antigen processing and presentation,M001,1,0
1,0,0,-2.6,0,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M100,1,0
0,0,1,0,0,-3.6,GO:0019221,cytokine-mediated signaling pathway,M001,1,0
0,0,1,0,0,-2.9,GO:0042113,B cell activation,M001,1,0
1,0,0,-2.4,0,0,R-HSA-5654689,PI-3K cascade:FGFR1,M100,1,0
0,0,1,0,0,-2,GO:0048015,phosphatidylinositol-mediated signaling,M001,1,0
0,0,1,0,0,-2.4,hsa04611,Platelet activation,M001,1,0
0,0,1,0,0,-2.3,GO:0031346,positive regulation of cell projection organization,M001,1,0
0,0,1,0,0,-3.3,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M001,1,0
1,0,0,-2.7,0,0,GO:0010762,regulation of fibroblast migration,M100,1,0
0,0,1,0,0,-3.1,R-HSA-9824443,Parasitic Infection Pathways,M001,1,0
0,0,1,0,0,-2.1,GO:0021801,cerebral cortex radial glia-guided migration,M001,1,0
0,0,1,0,0,-3.2,GO:0009617,response to bacterium,M001,1,0
0,0,1,0,0,-2.1,GO:1902305,regulation of sodium ion transmembrane transport,M001,1,0
0,0,1,0,0,-3.4,GO:0008283,cell population proliferation,M001,1,0
0,0,1,0,0,-2,WP289,Myometrial relaxation and contraction pathways,M001,1,0
0,1,0,0,-3.1,0,GO:0071674,mononuclear cell migration,M010,1,0
0,0,1,0,0,-2.6,GO:0051216,cartilage development,M001,1,0
0,0,1,0,0,-2.6,GO:0003231,cardiac ventricle development,M001,1,0
0,0,1,0,0,-5.1,GO:0006954,inflammatory response,M001,1,0
0,0,1,0,0,-2.4,GO:2001259,positive regulation of cation channel activity,M001,1,0
0,0,1,0,0,-3,GO:0048596,embryonic camera-type eye morphogenesis,M001,1,0
1,0,0,-2.3,0,0,GO:0050708,regulation of protein secretion,M100,1,0
0,0,1,0,0,-2,GO:0098743,cell aggregation,M001,1,0
0,0,1,0,0,-2.9,GO:0007605,sensory perception of sound,M001,1,0
0,0,1,0,0,-3.5,GO:0042472,inner ear morphogenesis,M001,1,0
1,0,0,-3.8,0,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M100,1,0
0,0,1,0,0,-2.4,GO:0031344,regulation of cell projection organization,M001,1,0
1,0,0,-2.4,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M100,1,0
0,0,1,0,0,-2.1,GO:0099536,synaptic signaling,M001,1,0
0,0,1,0,0,-2.6,GO:0002066,columnar/cuboidal epithelial cell development,M001,1,0
0,0,1,0,0,-2.3,GO:0032989,cellular anatomical entity morphogenesis,M001,1,0
0,0,1,0,0,-2.7,GO:0046643,regulation of gamma-delta T cell activation,M001,1,0
0,0,1,0,0,-3.3,GO:0001501,skeletal system development,M001,1,0
0,0,1,0,0,-2.2,GO:0048858,cell projection morphogenesis,M001,1,0
1,0,0,-2.4,0,0,GO:0045667,regulation of osteoblast differentiation,M100,1,0
0,0,1,0,0,-2.2,hsa05418,Fluid shear stress and atherosclerosis,M001,1,0
1,0,0,-2.2,0,0,R-HSA-157118,Signaling by NOTCH,M100,1,0
0,0,1,0,0,-2.3,R-HSA-446728,Cell junction organization,M001,1,0
0,1,0,0,-2.3,0,GO:0006885,regulation of pH,M010,1,0
0,0,1,0,0,-3.2,M8626,SIG BCR SIGNALING PATHWAY,M001,1,0
0,0,1,0,0,-3.7,GO:0021960,anterior commissure morphogenesis,M001,1,0
0,1,0,0,-2.8,0,GO:0050801,monoatomic ion homeostasis,M010,1,0
0,0,1,0,0,-3.2,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M001,1,0
1,0,0,-2,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
1,0,0,-2.5,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M010,1,0
0,1,0,0,-2,0,GO:1900180,regulation of protein localization to nucleus,M010,1,0
0,0,1,0,0,-2.6,WP4541,Hippo Merlin signaling dysregulation,M001,1,0
0,0,1,0,0,-3.4,R-HSA-1236977,Endosomal/Vacuolar pathway,M001,1,0
0,0,1,0,0,-2.4,GO:0001837,epithelial to mesenchymal transition,M001,1,0
0,0,1,0,0,-2.3,GO:1904064,positive regulation of cation transmembrane transport,M001,1,0
0,0,1,0,0,-2.2,GO:0007389,pattern specification process,M001,1,0
0,0,1,0,0,-2,GO:0060576,intestinal epithelial cell development,M001,1,0
0,1,0,0,-2.2,0,GO:0071774,response to fibroblast growth factor,M010,1,0
0,1,0,0,-2.2,0,GO:0003044,regulation of systemic arterial blood pressure mediated by a chemical signal,M010,1,0
1,0,0,-2.2,0,0,GO:0032653,regulation of interleukin-10 production,M100,1,0
0,0,1,0,0,-2.2,hsa04612,Antigen processing and presentation,M001,1,0
0,0,1,0,0,-2.2,GO:0032414,positive regulation of ion transmembrane transporter activity,M001,1,0
0,0,1,0,0,-2.7,GO:0010002,cardioblast differentiation,M001,1,0
0,0,1,0,0,-3.2,GO:0007167,enzyme-linked receptor protein signaling pathway,M001,1,0
1,0,0,-2.2,0,0,GO:0002067,glandular epithelial cell differentiation,M100,1,0
0,0,1,0,0,-2.2,R-HSA-9762293,Regulation of CDH11 gene transcription,M001,1,0
1,0,0,-2.7,0,0,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M100,1,0
0,0,1,0,0,-3.9,GO:0035107,appendage morphogenesis,M001,1,0
0,1,0,0,-2.3,0,GO:0042307,positive regulation of protein import into nucleus,M010,1,0
0,0,1,0,0,-3.5,GO:0051336,regulation of hydrolase activity,M001,1,0
1,0,0,-2.1,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0009988,cell-cell recognition,M010,1,0
0,0,1,0,0,-2,GO:0048644,muscle organ morphogenesis,M001,1,0
0,0,1,0,0,-2,GO:0051146,striated muscle cell differentiation,M001,1,0
1,0,0,-2.1,0,0,GO:0002701,negative regulation of production of molecular mediator of immune response,M100,1,0
1,0,0,-3.1,0,0,GO:0045596,negative regulation of cell differentiation,M100,1,0
0,0,1,0,0,-2.9,GO:0098742,cell-cell adhesion via plasma-membrane adhesion molecules,M001,1,0
0,0,1,0,0,-2.3,GO:0035904,aorta development,M001,1,0
0,0,1,0,0,-2.4,R-HSA-2424491,DAP12 signaling,M001,1,0
0,0,1,0,0,-2.3,GO:0120039,plasma membrane bounded cell projection morphogenesis,M001,1,0
0,1,0,0,-2.7,0,GO:0051453,regulation of intracellular pH,M010,1,0
0,1,0,0,-2.4,0,GO:0009101,glycoprotein biosynthetic process,M010,1,0
1,0,0,-2.4,0,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
0,0,1,0,0,-2.8,GO:0002064,epithelial cell development,M001,1,0
1,0,0,-2.2,0,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M100,1,0
0,1,0,0,-2.5,0,GO:0060326,cell chemotaxis,M010,1,0
0,1,0,0,-2.2,0,R-HSA-9706369,Negative regulation of FLT3,M010,1,0
0,0,1,0,0,-3.1,GO:0071695,anatomical structure maturation,M001,1,0
0,0,1,0,0,-2.8,GO:0003205,cardiac chamber development,M001,1,0
1,0,0,-2,0,0,GO:0043068,positive regulation of programmed cell death,M100,1,0
1,0,0,-3.1,0,0,GO:0045669,positive regulation of osteoblast differentiation,M100,1,0
0,0,1,0,0,-2.5,GO:0010720,positive regulation of cell development,M001,1,0
0,0,1,0,0,-4.7,GO:0032760,positive regulation of tumor necrosis factor production,M001,1,0
0,1,0,0,-2.5,0,GO:1990573,potassium ion import across plasma membrane,M010,1,0
0,0,1,0,0,-3.3,GO:1903706,regulation of hemopoiesis,M001,1,0
0,0,1,0,0,-2.4,GO:0045664,regulation of neuron differentiation,M001,1,0
0,0,1,0,0,-2.2,GO:0060415,muscle tissue morphogenesis,M001,1,0
1,0,0,-2.4,0,0,GO:0045059,positive thymic T cell selection,M100,1,0
0,0,1,0,0,-2.1,GO:0009792,embryo development ending in birth or egg hatching,M001,1,0
0,0,1,0,0,-2.9,GO:0072132,mesenchyme morphogenesis,M001,1,0
1,0,0,-2.5,0,0,WP2023,Cell differentiation expanded index,M100,1,0
0,1,0,0,-2.4,0,GO:0106030,neuron projection fasciculation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-5628897,TP53 Regulates Metabolic Genes,M100,1,0
1,0,0,-2.1,0,0,WP3967,miR 509 3p alteration of YAP1 ECM axis,M100,1,0
0,1,0,0,-2.4,0,GO:0045780,positive regulation of bone resorption,M010,1,0
0,1,0,0,-2.7,0,GO:0030575,nuclear body organization,M010,1,0
0,0,1,0,0,-2.5,GO:0061036,positive regulation of cartilage development,M001,1,0
0,0,1,0,0,-3.1,WP286,IL 3 signaling pathway,M001,1,0
0,0,1,0,0,-2.7,GO:0008015,blood circulation,M001,1,0
1,0,0,-3.6,0,0,GO:0045824,negative regulation of innate immune response,M100,1,0
1,0,0,-3.6,0,0,GO:0044092,negative regulation of molecular function,M100,1,0
1,0,0,-2.3,0,0,GO:0002820,negative regulation of adaptive immune response,M100,1,0
0,0,1,0,0,-2.7,GO:0042692,muscle cell differentiation,M001,1,0
1,0,0,-3.4,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
0,0,1,0,0,-2.2,GO:0090103,cochlea morphogenesis,M001,1,0
0,1,0,0,-2.1,0,WP3640,Imatinib and chronic myeloid leukemia,M010,1,0
0,0,1,0,0,-2.4,GO:0072576,liver morphogenesis,M001,1,0
1,0,0,-2.5,0,0,R-HSA-1839124,FGFR1 mutant receptor activation,M100,1,0
0,1,0,0,-2.8,0,GO:0061024,membrane organization,M010,1,0
0,0,1,0,0,-4.8,GO:0048562,embryonic organ morphogenesis,M001,1,0
0,0,1,0,0,-4.1,GO:0002697,regulation of immune effector process,M001,1,0
1,0,0,-2,0,0,GO:1904705,regulation of vascular associated smooth muscle cell proliferation,M100,1,0
0,0,1,0,0,-3,R-HSA-2172127,DAP12 interactions,M001,1,0
0,0,1,0,0,-3,GO:0051048,negative regulation of secretion,M001,1,0
1,0,0,-3,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
0,0,1,0,0,-3,GO:0051607,defense response to virus,M001,1,0
1,0,0,-3.3,0,0,hsa04148,Efferocytosis,M100,1,0
0,0,1,0,0,-2.1,GO:0048704,embryonic skeletal system morphogenesis,M001,1,0
0,0,1,0,0,-2.1,GO:0055117,regulation of cardiac muscle contraction,M001,1,0
1,0,0,-2.5,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
1,0,0,-2.8,0,0,hsa04659,Th17 cell differentiation,M100,1,0
1,0,0,-2.5,0,0,GO:0002719,negative regulation of cytokine production involved in immune response,M100,1,0
0,0,1,0,0,-2.9,hsa05202,Transcriptional misregulation in cancer,M001,1,0
0,1,0,0,-2.5,0,GO:2001233,regulation of apoptotic signaling pathway,M010,1,0
1,0,0,-2.1,0,0,GO:0045860,positive regulation of protein kinase activity,M100,1,0
0,0,1,0,0,-3.1,GO:0032409,regulation of transporter activity,M001,1,0
0,0,1,0,0,-2.8,GO:0032673,regulation of interleukin-4 production,M001,1,0
1,0,0,-2.6,0,0,M33,PID GLYPICAN 1PATHWAY,M100,1,0
1,0,0,-2.9,0,0,GO:0070371,ERK1 and ERK2 cascade,M100,1,0
0,1,0,0,-2.4,0,GO:0070100,negative regulation of chemokine-mediated signaling pathway,M010,1,0
0,0,1,0,0,-3.1,M223,PID BETA CATENIN NUC PATHWAY,M001,1,0
0,0,1,0,0,-2.2,GO:0043009,chordate embryonic development,M001,1,0
1,0,0,-2.6,0,0,GO:0040008,regulation of growth,M100,1,0
0,0,1,0,0,-2.8,GO:0032479,regulation of type I interferon production,M001,1,0
0,1,0,0,-2.4,0,WP1772,Apoptosis modulation and signaling,M010,1,0
1,0,0,-2.5,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
1,0,0,-2.7,0,0,GO:0060336,negative regulation of type II interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0032722,positive regulation of chemokine production,M100,1,0
0,0,1,0,0,-2.5,GO:0090287,regulation of cellular response to growth factor stimulus,M001,1,0
0,0,1,0,0,-2.3,GO:0001568,blood vessel development,M001,1,0
1,0,0,-2.4,0,0,GO:0043537,negative regulation of blood vessel endothelial cell migration,M100,1,0
0,0,1,0,0,-2.9,GO:0050764,regulation of phagocytosis,M001,1,0
1,0,0,-2.8,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-3.1,0,0,R-HSA-111448,Activation of NOXA and translocation to mitochondria,M100,1,0
1,0,0,-2.6,0,0,GO:0090398,cellular senescence,M100,1,0
0,0,1,0,0,-2.7,GO:0030859,polarized epithelial cell differentiation,M001,1,0
0,0,1,0,0,-2.5,GO:0014896,muscle hypertrophy,M001,1,0
0,0,1,0,0,-2,GO:0030810,positive regulation of nucleotide biosynthetic process,M001,1,0
1,0,0,-3.7,0,0,WP2795,Cardiac hypertrophic response,M100,1,0
0,1,0,0,-2.4,0,GO:0035455,response to interferon-alpha,M010,1,0
0,0,1,0,0,-3.8,GO:0002833,positive regulation of response to biotic stimulus,M001,1,0
0,0,1,0,0,-2.2,GO:0060638,mesenchymal-epithelial cell signaling,M001,1,0
0,0,1,0,0,-2.8,WP3931,Embryonic stem cell pluripotency pathways,M001,1,0
0,0,1,0,0,-2.2,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M001,1,0
0,0,1,0,0,-2.7,GO:0002483,antigen processing and presentation of endogenous peptide antigen,M001,1,0
0,0,1,0,0,-2.8,GO:0022029,telencephalon cell migration,M001,1,0
1,0,0,-2.7,0,0,GO:0060331,negative regulation of response to type II interferon,M100,1,0
0,0,1,0,0,-2.6,GO:0045621,positive regulation of lymphocyte differentiation,M001,1,0
1,0,0,-2.4,0,0,GO:0048663,neuron fate commitment,M100,1,0
0,0,1,0,0,-2.4,GO:0060900,embryonic camera-type eye formation,M001,1,0
0,0,1,0,0,-2.1,M54,PID IL12 2PATHWAY,M001,1,0
0,0,1,0,0,-4.4,GO:0032103,positive regulation of response to external stimulus,M001,1,0
0,0,1,0,0,-2.9,GO:0001959,regulation of cytokine-mediated signaling pathway,M001,1,0
0,0,1,0,0,-3.4,WP4217,Ebola virus infection in host,M001,1,0
0,0,1,0,0,-2.1,GO:0002708,positive regulation of lymphocyte mediated immunity,M001,1,0
0,0,1,0,0,-3.6,GO:0001916,positive regulation of T cell mediated cytotoxicity,M001,1,0
0,0,1,0,0,-3.4,GO:1904062,regulation of monoatomic cation transmembrane transport,M001,1,0
0,0,1,0,0,-2.4,GO:0002428,antigen processing and presentation of peptide antigen via MHC class Ib,M001,1,0
0,0,1,0,0,-2,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M001,1,0
0,0,1,0,0,-2.4,R-HSA-2871796,FCERI mediated MAPK activation,M001,1,0
0,0,1,0,0,-2.5,GO:0061035,regulation of cartilage development,M001,1,0
0,1,0,0,-2.2,0,R-HSA-75158,TRAIL  signaling,M010,1,0
0,0,1,0,0,-3.8,GO:0002887,negative regulation of myeloid leukocyte mediated immunity,M001,1,0
1,0,0,-2.3,0,0,GO:0001667,ameboidal-type cell migration,M100,1,0
0,0,1,0,0,-2.5,GO:0003214,cardiac left ventricle morphogenesis,M001,1,0
1,0,0,-2.3,0,0,GO:0045687,positive regulation of glial cell differentiation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M100,1,0
0,0,1,0,0,-3.9,GO:0030100,regulation of endocytosis,M001,1,0
0,1,0,0,-2.9,0,GO:0002526,acute inflammatory response,M010,1,0
0,1,0,0,-2.9,0,GO:0031330,negative regulation of cellular catabolic process,M010,1,0
0,0,1,0,0,-2.2,GO:0046641,positive regulation of alpha-beta T cell proliferation,M001,1,0
0,0,1,0,0,-2.4,GO:0060021,roof of mouth development,M001,1,0
0,0,1,0,0,-2.4,GO:0072574,hepatocyte proliferation,M001,1,0
1,0,0,-2.4,0,0,GO:0048864,stem cell development,M100,1,0
0,0,1,0,0,-4,GO:0051051,negative regulation of transport,M001,1,0
0,0,1,0,0,-2.3,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M001,1,0
0,0,1,0,0,-2.2,GO:0001738,morphogenesis of a polarized epithelium,M001,1,0
0,0,1,0,0,-2,GO:0045198,establishment of epithelial cell apical/basal polarity,M001,1,0
0,0,1,0,0,-2.6,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M001,1,0
1,0,0,-2.9,0,0,GO:0060330,regulation of response to type II interferon,M100,1,0
0,0,1,0,0,-2.2,GO:0002053,positive regulation of mesenchymal cell proliferation,M001,1,0
0,0,1,0,0,-2.2,hsa04145,Phagosome,M001,1,0
1,0,0,-2.1,0,0,M290,PID IL12 STAT4 PATHWAY,M100,1,0
0,1,0,0,-2.1,0,GO:0031398,positive regulation of protein ubiquitination,M010,1,0
0,0,1,0,0,-2.3,GO:0035050,embryonic heart tube development,M001,1,0
0,0,1,0,0,-2,GO:0021542,dentate gyrus development,M001,1,0
0,0,1,0,0,-2.4,GO:0060333,type II interferon-mediated signaling pathway,M001,1,0
1,0,0,-2.3,0,0,GO:0043368,positive T cell selection,M100,1,0
0,0,1,0,0,-3.4,GO:0060537,muscle tissue development,M001,1,0
0,0,1,0,0,-2.3,GO:0090066,regulation of anatomical structure size,M001,1,0
0,0,1,0,0,-2.1,GO:0034764,positive regulation of transmembrane transport,M001,1,0
0,1,0,0,-2.6,0,hsa05221,Acute myeloid leukemia,M010,1,0
1,0,0,-2.4,0,0,R-HSA-190373,FGFR1c ligand binding and activation,M100,1,0
0,0,1,0,0,-5.1,GO:0048568,embryonic organ development,M001,1,0
0,0,1,0,0,-3.1,R-HSA-9658195,Leishmania infection,M001,1,0
0,0,1,0,0,-2,GO:0003281,ventricular septum development,M001,1,0
1,0,0,-2.4,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
0,0,1,0,0,-2.7,hsa05203,Viral carcinogenesis,M001,1,0
1,0,0,-3.2,0,0,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M100,1,0
0,0,1,0,0,-3.4,GO:0050865,regulation of cell activation,M001,1,0
0,0,1,0,0,-2.7,GO:1904862,inhibitory synapse assembly,M001,1,0
1,0,0,-2.7,0,0,R-HSA-9700645,ALK mutants bind TKIs,M100,1,0
0,0,1,0,0,-3.3,GO:0002703,regulation of leukocyte mediated immunity,M001,1,0
1,0,0,-3.2,0,0,hsa04061,Viral protein interaction with cytokine and cytokine receptor,M100,1,0
1,0,0,-2,0,0,GO:2001054,negative regulation of mesenchymal cell apoptotic process,M100,1,0
1,0,0,-3.4,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M100,1,0
0,1,0,0,-2.5,0,GO:1900182,positive regulation of protein localization to nucleus,M010,1,0
0,0,1,0,0,-4.6,GO:0061061,muscle structure development,M001,1,0
0,0,1,0,0,-2.4,GO:0048565,digestive tract development,M001,1,0
1,0,0,-2.1,0,0,GO:0002710,negative regulation of T cell mediated immunity,M100,1,0
1,0,0,-2.7,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2,0,0,GO:1904672,regulation of somatic stem cell population maintenance,M100,1,0
0,1,0,0,-2.1,0,GO:0007033,vacuole organization,M010,1,0
1,0,0,-2.4,0,0,GO:0003416,endochondral bone growth,M100,1,0
0,0,1,0,0,-2.3,R-HSA-909733,Interferon alpha/beta signaling,M001,1,0
1,0,0,-2.7,0,0,R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,M100,1,0
0,0,1,0,0,-2.5,GO:0045582,positive regulation of T cell differentiation,M001,1,0
0,0,1,0,0,-3.1,GO:0048048,embryonic eye morphogenesis,M001,1,0
1,0,0,-2.7,0,0,GO:1904892,regulation of receptor signaling pathway via STAT,M100,1,0
1,0,0,-3.1,0,0,GO:0060420,regulation of heart growth,M100,1,0
0,0,1,0,0,-2.4,GO:0010880,regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,M001,1,0
1,0,0,-2,0,0,R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,M100,1,0
0,1,0,0,-2.2,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M010,1,0
1,0,0,-2.2,0,0,GO:0070243,regulation of thymocyte apoptotic process,M100,1,0
0,1,0,0,-2.1,0,M17,PID NOTCH PATHWAY,M010,1,0
0,0,1,0,0,-2.2,WP4211,Transcriptional cascade regulating adipogenesis,M001,1,0
0,0,1,0,0,-2.5,GO:0035051,cardiocyte differentiation,M001,1,0
0,0,1,0,0,-2,GO:0002758,innate immune response-activating signaling pathway,M001,1,0
0,0,1,0,0,-2.9,R-HSA-9843745,Adipogenesis,M001,1,0
0,0,1,0,0,-2.7,GO:0097067,cellular response to thyroid hormone stimulus,M001,1,0
1,0,0,-2.7,0,0,GO:1903053,regulation of extracellular matrix organization,M100,1,0
0,0,1,0,0,-2.3,GO:0034330,cell junction organization,M001,1,0
1,0,0,-2,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
0,0,1,0,0,-2.4,GO:0002263,cell activation involved in immune response,M001,1,0
1,0,0,-2.2,0,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M100,1,0
0,0,1,0,0,-2.2,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,M001,1,0
0,1,0,0,-3.3,0,GO:0046822,regulation of nucleocytoplasmic transport,M010,1,0
0,0,1,0,0,-3,GO:0043410,positive regulation of MAPK cascade,M001,1,0
0,0,1,0,0,-2.6,GO:0021885,forebrain cell migration,M001,1,0
1,0,0,-2.4,0,0,GO:0090077,foam cell differentiation,M100,1,0
0,0,1,0,0,-2,GO:0021889,olfactory bulb interneuron differentiation,M001,1,0
0,0,1,0,0,-2.9,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M001,1,0
0,1,0,0,-2,0,GO:0061842,microtubule organizing center localization,M010,1,0
0,0,1,0,0,-4.2,GO:0031349,positive regulation of defense response,M001,1,0
0,1,0,0,-2.4,0,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M010,1,0
0,0,1,0,0,-2.1,GO:0120035,regulation of plasma membrane bounded cell projection organization,M001,1,0
0,1,0,0,-3.3,0,GO:0032386,regulation of intracellular transport,M010,1,0
0,0,1,0,0,-2.9,GO:0071772,response to BMP,M001,1,0
0,0,1,0,0,-2.9,GO:0045586,regulation of gamma-delta T cell differentiation,M001,1,0
0,0,1,0,0,-3.3,GO:0022604,regulation of cell morphogenesis,M001,1,0
1,0,0,-3.4,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
0,0,1,0,0,-2.1,hsa05322,Systemic lupus erythematosus,M001,1,0
0,0,1,0,0,-2.5,GO:0007219,Notch signaling pathway,M001,1,0
0,1,0,0,-2.4,0,GO:0007413,axonal fasciculation,M010,1,0
0,0,1,0,0,-2.5,GO:0060411,cardiac septum morphogenesis,M001,1,0
1,0,0,-3.3,0,0,GO:0001818,negative regulation of cytokine production,M100,1,0
0,0,1,0,0,-3.7,M183,PID IL6 7 PATHWAY,M001,1,0
0,1,0,0,-2.1,0,R-HSA-400253,Circadian Clock,M010,1,0
1,0,0,-2.2,0,0,GO:0061383,trabecula morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0060043,regulation of cardiac muscle cell proliferation,M100,1,0
0,0,1,0,0,-2.4,GO:0002475,antigen processing and presentation via MHC class Ib,M001,1,0
0,1,0,0,-3.5,0,R-HSA-9607240,FLT3 Signaling,M010,1,0
0,1,0,0,-2.8,0,hsa05207,Chemical carcinogenesis - receptor activation,M010,1,0
0,0,1,0,0,-2.5,GO:0045807,positive regulation of endocytosis,M001,1,0
0,0,1,0,0,-2.4,GO:0051249,regulation of lymphocyte activation,M001,1,0
0,0,1,0,0,-2.4,M5493,WNT SIGNALING,M001,1,0
1,0,0,-3.1,0,0,R-HSA-1839122,Signaling by activated point mutants of FGFR1,M100,1,0
0,1,0,0,-2.3,0,GO:0006873,intracellular monoatomic ion homeostasis,M010,1,0
0,0,1,0,0,-3.9,GO:0035108,limb morphogenesis,M001,1,0
1,0,0,-2.5,0,0,GO:0072207,metanephric epithelium development,M100,1,0
0,0,1,0,0,-2,GO:0043301,negative regulation of leukocyte degranulation,M001,1,0
